# Phosphodiesterase function and regulation **Type:** Topics **Canonical URL:** https://scholariq.org/topics/phosphodiesterase-function-and-regulation/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the molecular regulation and clinical applications of cyclic nucleotide phosphodiesterases (PDEs), particularly in the context of cAMP signaling, schizophrenia genetics, neuronal development, therapeutic targeting, compartmentalized signaling, Alzheimer's disease treatment, cardiac function regulation, and the development of phosphodiesterase inhibitors. | | Domain | Life Sciences | | Field | Biochemistry, Genetics and Molecular Biology | | OpenAlex ID | t12434 | | Works | 69 | ## Topic papers all Showing 15 of 69. - [Selexipag for the Treatment of Pulmonary Arterial Hypertension](https://scholariq.org/papers/selexipag-for-the-treatment-of-pulmonary-arterial-hypertension/) - [Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction](https://scholariq.org/papers/phenotype-specific-treatment-of-heart-failure-with-preserved-ejection-fraction/) - [Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function](https://scholariq.org/papers/phosphodiesterase-5-inhibition-augments-endogenous-antitumor-immunity-by/) - [Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial](https://scholariq.org/papers/safety-and-efficacy-of-erenumab-for-preventive-treatment-of-chronic-migraine-a/) - [Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension](https://scholariq.org/papers/randomized-study-of-adding-inhaled-iloprost-to-existing-bosentan-in-pulmonary/) - [Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia](https://scholariq.org/papers/association-of-diabetes-mellitus-with-use-of-atypical-neuroleptics-in-the/) - [Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases](https://scholariq.org/papers/phosphodiesterase-4-inhibitors-for-the-treatment-of-inflammatory-diseases/) - [Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)](https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/) - [Dysfunctional Voltage-Gated K + Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension](https://scholariq.org/papers/dysfunctional-voltage-gated-k-sup-sup-channels-in-pulmonary-artery-smooth-muscle/) - [Association of DISC1/TRAX Haplotypes With Schizophrenia, Reduced Prefrontal Gray Matter, and Impaired Short- and Long-term Memory](https://scholariq.org/papers/association-of-disc1-trax-haplotypes-with-schizophrenia-reduced-prefrontal-gray/) - [Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)](https://scholariq.org/papers/apremilast-an-oral-phosphodiesterase-4-inhibitor-in-patients-with-psoriatic/) - [The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579](https://scholariq.org/papers/the-map-kinase-erk2-inhibits-the-cyclic-amp-specific-phosphodiesterase-hspde4d3/) - [L‐type calcium channel blockers and Parkinson disease in Denmark](https://scholariq.org/papers/l-type-calcium-channel-blockers-and-parkinson-disease-in-denmark/) - [Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension](https://scholariq.org/papers/long-term-use-of-sildenafil-in-inoperable-chronic-thromboembolic-pulmonary/) - [Which comes first: atypical antipsychotic treatment or cardiometabolic risk?](https://scholariq.org/papers/which-comes-first-atypical-antipsychotic-treatment-or-cardiometabolic-risk/) ## Topic primary papers Showing 15 of 21. - [Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function](https://scholariq.org/papers/phosphodiesterase-5-inhibition-augments-endogenous-antitumor-immunity-by/) - [Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases](https://scholariq.org/papers/phosphodiesterase-4-inhibitors-for-the-treatment-of-inflammatory-diseases/) - [Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)](https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/) - [Association of DISC1/TRAX Haplotypes With Schizophrenia, Reduced Prefrontal Gray Matter, and Impaired Short- and Long-term Memory](https://scholariq.org/papers/association-of-disc1-trax-haplotypes-with-schizophrenia-reduced-prefrontal-gray/) - [Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)](https://scholariq.org/papers/apremilast-an-oral-phosphodiesterase-4-inhibitor-in-patients-with-psoriatic/) - [The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579](https://scholariq.org/papers/the-map-kinase-erk2-inhibits-the-cyclic-amp-specific-phosphodiesterase-hspde4d3/) - [Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling](https://scholariq.org/papers/impact-of-the-disc1-ser704cys-polymorphism-on-risk-for-major-depression-brain/) - [Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene](https://scholariq.org/papers/characterization-of-five-different-proteins-produced-by-alternatively-spliced/) - [cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model](https://scholariq.org/papers/camp-specific-phosphodiesterase-hspde4d3-mutants-which-mimic-activation-and/) - [Role of cAMP and phosphodiesterase signaling in liver health and disease](https://scholariq.org/papers/role-of-camp-and-phosphodiesterase-signaling-in-liver-health-and-disease/) - [Inhibition of phosphodiesterase‐4 attenuates murine ulcerative colitis through interference with mucosal immunity](https://scholariq.org/papers/inhibition-of-phosphodiesterase-4-attenuates-murine-ulcerative-colitis-through/) - [Effects of phosphodiesterase‐5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial](https://scholariq.org/papers/effects-of-phosphodiesterase-5-inhibitors-on-leydig-cell-secretory-function-in/) - [Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors](https://scholariq.org/papers/treatment-with-bbb022a-or-rolipram-stabilizes-the-blood-brain-barrier-in/) - [Autosomal-Dominant Striatal Degeneration Is Caused by a Mutation in the Phosphodiesterase 8B Gene](https://scholariq.org/papers/autosomal-dominant-striatal-degeneration-is-caused-by-a-mutation-in-the/) - [The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells](https://scholariq.org/papers/the-camp-phosphodiesterase-4d7-pde4d7-is-downregulated-in-androgen-independent/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.